Atlas Trials

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

Clinical trial NCT04007978 · UNKNOWN

Trial details

NCT number
NCT04007978
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
B Cell LymphomaAcute Lymphoblastic Leukemia
Start date
2019-08-05
Primary completion
2022-06-30
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.